Document is current

Article History

Received: 7 October 2021

Accepted: 13 October 2021

First Online: 23 November 2021

Declarations

:

: BB reports receipt of lecture fees from Chiesi, AstraZeneca, and GlaxoSmithKline. All were outside the scope of this manuscript. EC reports receipt of honoraria for advisory boards or speaking events from Chiesi Farmaceutici, Astra-Zeneca, Guidotti-Malesci, Menarini Group, GlaxoSmithKline, Boehringer-Ingelheim, and Novartis. Institutional academic research was partly supported with research funding by Chiesi Farmaceutici and GlaxoSmithKline. All were outside the scope of this manuscript. LMF received consulting fees from Chiesi Farmaceutici, payment or honoraria for advisory boards or speaking events from Chiesi Farmaceutici, AstraZeneca, GlaxoSmithKline, Alfasigma, Novartis, and Verona Pharma, reimbursement of travel expenses from Chiesi Farmaceutici, Novartis, and Menarini, and participated in a data safety monitoring board or advisory board with Novartis and Chiesi. All were outside the scope of this manuscript.

: Not applicable.

: Not applicable.

: Not applicable.